While BDNF supplementation and miR-155 antagonists should be explored for their therapeutic potential in mitigating IBD-induced cardiac remodeling/HF, we cannot rule out other factors that may contribute to cardiac remodeling in IBD. This evidence concerns the gene BDNF and inflammatory bowel disease.